Neuren Pharmaceuticals Ltd (ASX: NEU) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Neuren Pharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $2.56 billion
P/E Ratio 16.58
Dividend Yield 0.00%
Shares Outstanding 130.07 million
Earnings per share 1.201
Dividend per share N/A
Year To Date Return -20.26%
Earnings Yield 6.03%
Franking -
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • Neuren Pharmaceuticals Ltd (ASX: NEU)
    Latest News

    A man holding a cup of coffee puts his thumb up and smiles while at laptop.

    3 reasons to be positive on ASX 200 shares in FY25 (and 3 to be wary)

    Vinay Ranjan from Airlie Funds Management says we should ignore market noise and buy quality stocks.

    Read more »

    Health workers shake hands and congratulate each other on good news.
    Healthcare Shares

    This ASX 200 healthcare stock is up 48% in a year, but one director is still buying!

    A director of this ASX 200 healthcare company has just lifted his personal stake by 50%.

    Read more »

    a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
    Broker Notes

    These ASX shares could rise 25% to 35%

    Analysts are tipping these shares to rise strongly from where they trade today.

    Read more »

    A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash
    Share Fallers

    Why Cettire, Neuren, Peter Warren, and Qantas shares are falling today

    These shares are having a tough time on hump day. But why?

    Read more »

    Shot of a young scientist using a digital tablet while working in a lab.
    Healthcare Shares

    Which ASX biotech shares are pioneering the future of medicine?

    Uncover the risks and rewards of high-stakes investments in ASX biotech stocks.

    Read more »

    A young woman holds her hand to her mouth in surprise as she reads something on her laptop.
    Healthcare Shares

    This ASX 200 stock can rocket to a record high: Broker

    This high-flying stock is far from having its wings clipped.

    Read more »

    A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
    Share Market News

    5 things to watch on the ASX 200 on Tuesday

    Another good session is expected for Aussie investors today.

    Read more »

    A neon sign says 'Top Ten'.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    The ASX 200 was back to the races today.

    Read more »

    Two colleagues at work looking at a tablet and smiling at a rising share price.
    Share Gainers

    Why Cettire, Lendlease, Neuren, and Sayona Mining shares are racing higher today

    These ASX shares are starting the week strongly. But why?

    Read more »

    Shot of a young scientist using a digital tablet while working in a lab.
    Share Gainers

    Guess which ASX 200 healthcare share just rocketed 11% on 'groundbreaking trial'

    Up 67% in a year, investors are sending the ASX 200 healthcare share soaring again today.

    Read more »

    pause in medical asx share price represented by doctor holding hand up in stop motion
    Healthcare Shares

    ASX 200 healthcare stock up 40% in 6 months halted ahead of major trial results

    Neuren Pharmaceuticals will reveal Phase 2 clinical results for its second drug candidate shortly.

    Read more »

    two magicians wearing dinner suits with bow ties wave their magic wands over a levitating bag with a dollars sign on it.
    Share Market News

    ASX 200 shares vs. property: Which has performed better since the COVID crash?

    We reveal which property markets and ASX 200 shares have risen the most since COVID-19 hit us.

    Read more »

    Frequently Asked Questions

    No, Neuren Pharmaceuticals does not pay dividends at this time. 

    Neuren Pharmaceuticals Limited (ASX: NEU) listed on the ASX on 3 February 2005.

    NEU ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Neuren Pharmaceuticals Ltd

    Neuren Pharmaceuticals Limited (ASX: NEU) is a biopharmaceutical company specialising in developing new therapies for neurodevelopmental disorders that emerge in early childhood and are characterised by impaired connections and signalling between brain cells. 

    In March 2023, the US Food and Drug Administration approved DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adults and children two years and older. Neuren's US partner Acadia Pharmaceuticals (NASDAQ: ACAD) holds a worldwide exclusive licence from Neuren for trofinetide. At this time, DAYBUE is the first and only drug approved for the treatment of Rett syndrome. Trofinetide has also demonstrated clinical benefit in a Phase 2 trial in treating Fragile X syndrome.

    Neuren's second product NNZ-2591 is currently in Phase 2 clinical trials for the treatment of Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome, and Prader-Willi syndrome. The drug candidate has shown positive effects in mouse models of each syndrome and was successful in a Phase 1 clinical trial. The number of patients across these four disorders is estimated as five times the number of Rett syndrome patients. There are currently no drugs approved for these conditions, apart from growth hormone to treat some aspects of Prader-Willi. 

    Acadia Pharmaceuticals also holds a worldwide exclusive licence to develop and commercialise NNZ-2591 for Rett syndrome and Fragile X syndrome. Neuren retains worldwide rights to NNZ-2591 in all other indications.

    NEU Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    21 Jun 2024 $20.00 $0.09 0.45% 591,493 $19.88 $20.07 $19.73
    20 Jun 2024 $19.91 $-0.03 -0.15% 417,369 $19.95 $20.00 $19.50
    19 Jun 2024 $19.94 $-0.04 -0.20% 240,790 $19.92 $20.04 $19.51
    18 Jun 2024 $19.98 $0.18 0.91% 320,620 $19.95 $20.18 $19.59
    17 Jun 2024 $19.80 $0.30 1.54% 271,475 $19.49 $19.92 $19.25
    14 Jun 2024 $19.50 $0.19 0.98% 374,137 $19.39 $19.98 $19.38
    13 Jun 2024 $19.31 $0.49 2.60% 402,851 $19.14 $19.43 $18.88
    12 Jun 2024 $18.82 $-0.20 -1.05% 380,942 $18.96 $19.06 $18.72
    11 Jun 2024 $19.02 $-0.45 -2.31% 623,804 $19.49 $19.56 $18.60
    07 Jun 2024 $19.47 $0.08 0.41% 488,185 $19.58 $19.85 $19.23
    06 Jun 2024 $19.39 $0.05 0.26% 599,508 $19.60 $19.65 $19.00
    05 Jun 2024 $19.34 $0.32 1.68% 728,431 $19.20 $19.41 $18.55
    04 Jun 2024 $19.02 $-1.25 -6.17% 1,034,242 $20.40 $20.50 $18.82
    03 Jun 2024 $20.27 $-1.37 -6.33% 531,929 $21.62 $21.63 $20.24
    31 May 2024 $21.64 $0.92 4.44% 890,818 $20.86 $21.64 $20.56
    30 May 2024 $20.72 $-0.24 -1.15% 767,025 $21.00 $21.21 $20.31
    29 May 2024 $20.96 $-2.15 -9.30% 1,142,818 $22.50 $22.70 $20.28
    28 May 2024 $23.11 $-0.86 -3.59% 985,075 $23.93 $23.97 $23.05
    27 May 2024 $23.97 $3.26 15.74% 1,182,630 $23.00 $24.00 $21.60
    22 May 2024 $20.71 $-0.02 -0.10% 263,091 $20.90 $21.30 $20.49

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    11 Jun 2024 Joseph(Joe) Basile Buy 5,000 $97,450
    On-market trade.
    13 Sep 2023 Joseph(Joe) Basile Buy 5,000 $59,950
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Trevor D Scott Non-Executive Director Mar 2002
    Dr Scott is the founder of T.D. Scott and Co., an accountancy and consulting firm, which he formed in 1988. He is an advisor to companies across industries. Trevor serves on corporate boards and is chairman of several.
    Ms Dianne Margaret Angus Non-Executive Director Jul 2018
    Mr Angus has executive managerial and company director experience in the biotechnology, biopharmaceutical, medical device, agritech and healthcare industries. Dianne has created global industry partnerships to yield medical, pharmaceutical and agricultural products. She has also driven the path for novel neurological pre-clinical agents to late-stage clinical assets before the FDA and European regulators. With over twenty five years' experience in ASX and NASDAQ listed companies, she has expertise in business development, capital raising and investor relations together with corporate governance and compliance capabilities. She is also a council member of Deakin University.
    Mr Jonathan (Jon) Charles Pilcher Chief Executive OfficerManaging Director Aug 2013
    Mr Pilcher was a member of the leadership team at Acrux throughout a period that included Acrux's IPO and listing on the ASX, the development and FDA approval of three novel pharmaceutical products and a transforming licensing deal with Eli Lilly in 2010. He formerly spent seven years in a series of executive positions in the R&D and corporate functions of international pharmaceutical groups Medeva and Celltech, which are now part of UCB.
    Dr Jenny Lee Harry Non-Executive Director Jul 2018
    Dr Harry has 20 years' experience in executive management of companies in the biotechnology and biopharmaceutical industry. Jenny is a CEO and Managing Director with experience in growing companies from start-up to commercialisation. She has served on Board's of listed and unlisted companies and on the Board's IP sub-committee of the Children's Medical Research Institute.
    Mr Patrick Davies Non-Executive DirectorNon-Executive Chairman Jul 2018
    Mr Davies has held executive management roles in the Australian and New Zealand healthcare industry for over twenty five years having performed in roles across industry sectors including pharmacy, primary care, pharmaceutical and consumer products. During his ten year period as Chief Executive Officer of EBOS Group Limited (and previously Symbion), the enterprise value of the group achieved compound annual growth in enterprise value of +20% (from circa $450M to in excess of $3.1B). He is a director on other corporate boards and provides advice to healthcare businesses and investors.
    Mr Joseph(Joe) Basile Non-Executive Director Mar 2023
    Mr Basile has held executive roles in the pharmaceutical industry for over 30 years, most recently as Group CFO at iNova Pharmaceuticals based in Singapore and prior to that with Novartis in senior Finance leadership and Commercial Sales roles in Australia and Asia.
    Ms Lauren Frazer Chief Financial OfficerCompany Secretary Aug 2020
    Lauren Frazer Chief Financial OfficerCompany Secretary
    Liza Squires Chief Medical Officerf
    Larry Glass Chief Science Officer
    Gerry Zhao Vice President Corporate Development
    Clive Blower Vice President Product Development

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Hsbc Custody Nominees (Australia) Limited 22,507,287 17.65%
    J P Morgan Nominees Australia Pty Limited 12,099,419 9.49%
    Citicorp Nominees Pty Limited 11,687,108 9.17%
    National Nominees Limited 4,166,698 3.27%
    Cameron Richard Pty Ltd 4,123,084 3.23%
    Bnp Paribas Noms Pty Ltd 3,584,206 2.81%
    Stuart Andrew Pty Ltd 2,633,787 2.07%
    Essex Castle Limited 2,387,678 1.87%
    Smithley Super Pty Ltd 1,870,000 1.47%
    Linwierik Super Pty Ltd 1,761,385 1.38%
    Sharesies Australia Nominee Pty Limited 1,435,555 1.13%
    Bnp Paribas Nominees Pty Ltd 796,367 0.62%
    First Colbyco Pty Ltd 750,000 0.59%
    Mjhft Pty Ltd 750,000 0.59%
    Bnp Paribas Nominees Pty Ltd Acf Clearstream 745,279 0.58%
    Dr Robin Lance Congreve 671,637 0.53%
    Hsbc Custody Nominees (Australia) Limited A/C 2 499,399 0.39%
    Emancipayte Pty Ltd 470,756 0.37%
    Netwealth Investments Limited 421,309 0.33%
    Mr He Zhao 405,000 0.32%
    Pfizer Inc 404,072 0.32%